Merck & Co., Inc. logo

Merck & Co., Inc. (MRK)

Market Closed
11 Jun, 20:00
$
80. 32
-1.03
-1.27%
$
196.54B Market Cap
58.39 P/E Ratio
3.08% Div Yield
11,795,094 Volume
1.46 Eps
$ 81.35
Previous Close
Day Range
79.98 81.68
Year Range
73.31 134.63
Earnings results expected in 47 days
Want to track MRK and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Here's Why Merck (MRK) Fell More Than Broader Market

Here's Why Merck (MRK) Fell More Than Broader Market

In the most recent trading session, Merck (MRK) closed at $80.32, indicating a -1.27% shift from the previous trading day.

Zacks | 2 hours ago
Merck (MRK) Rises Higher Than Market: Key Facts

Merck (MRK) Rises Higher Than Market: Key Facts

Merck (MRK) closed at $81.35 in the latest trading session, marking a +2.55% move from the prior day.

Zacks | 1 day ago
Merck: Best Case For Option Collars We'll Ever See

Merck: Best Case For Option Collars We'll Ever See

I use option collars on struggling stocks like Merck & Co., Inc. to cap downside risk while maintaining upside potential, especially when the technicals look uncertain. My MRK collar trade earlier this year limited losses compared to straight ownership, demonstrating why I favor this strategy for "dog" stocks. Currently, MRK stock shows potential for another collar setup, with defined risk and reward, though I haven't executed a new trade yet.

Seekingalpha | 1 day ago
Merck & Co., Inc. (MRK) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Merck & Co., Inc. (MRK) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Merck & Co., Inc. (NYSE:MRK ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:00 AM ET Company Participants Dean Y. Li - Executive VP & President of Merck Research Laboratories Robert M.

Seekingalpha | 1 day ago
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants

Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.

Zacks | 1 day ago
Will Merck's Keytruda Continue to Drive Growth Amid Looming LOE?

Will Merck's Keytruda Continue to Drive Growth Amid Looming LOE?

MRK leans on Keytruda for growth as exclusivity loss nears, with new combos and launches aiming to ease reliance.

Zacks | 1 day ago
Merck's cholesterol drug meets main goal in late-stage studies

Merck's cholesterol drug meets main goal in late-stage studies

Merck said on Monday its drug met the main goal of reducing a type of cholesterol in two late-stage studies.

Reuters | 2 days ago
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study

MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study

Merck reports promising response rates for its ADC zilovertamab vedotin in relapsed DLBCL and KRAS inhibitor MK-1084 in solid tumors.

Zacks | 1 week ago
Merck Stock's Ticking Keytruda Time Bomb

Merck Stock's Ticking Keytruda Time Bomb

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance is largely attributed to the phenomenal success of Keytruda, its blockbuster oncology drug.

Forbes | 1 week ago
Merck & Co., Inc. (MRK) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

Merck & Co., Inc. (MRK) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

Merck & Co., Inc. (NYSE:MRK ) Bernstein 41st Annual Strategic Decisions Conference May 29, 2025 3:30 PM ET Corporate Participants Rob Davis - Chairman and Chief Executive Officer Dean Li - Executive Vice President, President of Merck Research Labs Conference Call Participants Courtney Breen - Bernstein Courtney Breen All right. So, we might kick off our conversation with Merck today.

Seekingalpha | 1 week ago
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks | 1 week ago
Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn

Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck's (NYSE: MRK), known as MSD outside of the United States and Canada, patritumab deruxtecan (HER3-DXd) based on the HERTHENA-Lung01 phase 2 trial for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies has.

Businesswire | 1 week ago
Loading...
Load More